Bionic Sight

Executive Summary

Bionic Sight is a biotechnology company pioneering next-generation optogenetic gene therapies to restore vision in patients with advanced retinal degenerative diseases. Founded in 2017 and headquartered in New York, the company combines its proprietary gene therapy (BS01) with neural coding technology that reprograms the retina's output cells to send visual signals to the brain, bypassing damaged photoreceptors. This innovative approach targets the root cause of vision loss in conditions such as retinitis pigmentosa (RP) and geographic atrophy (GA) secondary to dry age-related macular degeneration, offering hope to patients with no effective treatment options currently available. Bionic Sight has two ongoing Phase 1/2 clinical trials for BS01: one in retinitis pigmentosa (NCT04278131, initiated February 2020) and another in geographic atrophy (NCT07158775, initiated January 2026). The RP trial is actively recruiting patients, with top-line data expected in the coming years that could provide initial proof-of-concept for the platform. The GA trial recently began enrollment, marking an expansion into a larger patient population. If successful, Bionic Sight's approach could address a significant unmet need in ophthalmology. The company remains private and has not disclosed recent funding rounds, but its scientific progress positions it as a potential acquisition target or candidate for future investment.

Upcoming Catalysts (preview)

• H2 2027Interim Phase 1/2 data for BS01 in Retinitis Pigmentosa60% success
• H1 2028Initial safety/efficacy data for BS01 in Geographic Atrophy (Phase 1/2)50% success
• Q4 2026Series B financing or strategic partnership announcement40% success